Review on Ischemic Heart Diseases and Its Medication
Ischemic heart diseases are a major public health problem, it includes disorders of the heart and blood vessel. Ischemia is a condition in which the blood flow (and thus oxygen) is restricted or reduced in a part of the body. Cardiac ischemia is the name for decreased blood flow and oxygen to the heart muscle. It's the term given to heart problems caused by narrowed heart arteries. When arteries are narrowed, less blood and oxygen reaches the heart muscle. This is also called coronary artery disease and coronary heart disease. This can ultimately lead to attack. Ischemia often causes chest pain or discomfort known as angina pectoris. Disease is diagnosed according to medical parameters; following diagnosis of the disease the treatment is started. The treatment is includes in medicines of Heart diseases and is as well as lifestyle.
2. Nitroglycerin Sublingual: MedlinePlus Drug Information". medlineplus.gov. Archived from the original on 6
3. "WHO Disease and injury country estimates". World Health Organization. 2009. Archived from the original on
11 November 2009. Retrieved 11 November 2009
4. Ambrose, John; Singh, Manmeet (2015). "Path physiology of coronary artery disease leading to acute coronary
5. American College of Cardiology (September 2013), "Five Things Physicians and Patients Should Question",
Choosing Wisely: an initiative of the ABIM Foundation, American College of Cardiology, archived from the
original on 17 December 2013, retrieved 10 February 2014
6. Erling Falk,Prediamn K. shah, Pim J. Feyter. Ischemic heart disease 1th edition. Burden on ischemic heart
diseases. Page no-15 -18
7. Erling Falk,Prediamn K. shah, Pim J. Feyter. Ischemic heart disease 1th edition. Anatomy of Heart. Page no: 20
8. Hackshaw, Allan; Morris, Joan K; Boniface, Sadie; Tang, Jin-Ling; Milenkovic, Dusan (24 January 2018). "Low
cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55
9. Kerola, AM; Kauppi, MJ; Kerola, T; Nieminen, TV (October 2012). "How early in the course of rheumatoid
arthritis does the excess cardiovascular risk appear?". Annals of the rheumatic diseases. 71 (10): 1606–15.
10. Kharade S.M, Rajmane M.A, Samudre P.A, Patil S.S. A Review: Etiology and Path physiology of Congestive
Heart Failure. International Journal of Pharmaceutical and Phytopharmacological Research, 2014; 3(5): 352-356.
11. Kontos, MC; Diercks, DB; Kirk, JD (Mar 2010). "Emergency department and office-based evaluation of
patients with chest pain". Mayo Clinic Proceedings. 85 (3): 284–99.
12.Kwak SM, Myung SK, Lee YJ, Seo HG (2012-04-09). "Efficacy of Omega-3 Fatty Acid Supplements
(Eicosapentaenoic Acid and Docosahexaenoic Acid) in the Secondary Prevention of Cardiovascular Disease: A
Meta-analysis of Randomized, Double-blind, Placebo-Controlled Trials". Archives of Internal Medicine. 172 (9):
13. Mendis, Shanthi Puska, Pekka; Norrving, Bo (2011). Global atlas on cardiovascular disease prevention and
control (PDF) (1st ed.). Geneva: World Health Organization in collaboration with the World Heart Federation and
the World Stroke Organization. pp. 3–18.
14. Ohman, EM (March 2016). "CLINICAL PRACTICE. Chronic Stable Angina". New England Journal of Medicine.
374 (12): 1167–76.
15. Schocken DD, Ischemic heart diseases: A scientific statement from the American Heart Association.
16. Stergiopoulos K, Boden WE, Hartigan P, Mobius-Winkler S, Hambrecht R, Hueb W, Hardison RM, Abbott JD,
Brown DL (2014). "Percutaneous coronary intervention outcomes in patients with stable obstructive coronary
artery disease and myocardial ischemia: a collaborative meta-analysis of contemporary randomized clinical
trials". JAMA Intern Med. 174 (2): 232–40.
17. Walker C, Reamy BV (April 2009). "Diets for cardiovascular disease prevention: what is the evidence?". Am
Fam Physician. 79 (7): 571–8.